The Prolaris Score is a genomic test that analyzes changes in 31 genes in prostate biopsy tissue to predict the potential risk of disease progression in men with localized prostate cancer. The test assesses PSA and Gleason results together with its cell cycle proliferation (CCP) score to provide a result from 0 to 10 about how aggressive the cancer is–the higher the number, the more aggressive the cancer. The Prolaris Score can help inform the decision about whether active surveillance, a single line of treatment, or a mult-modal approach to treatment is best for each unique patient.
Prolaris Test Benefits
- Two times more effective that the PSA and Gleason scores in predicting the risk of aggressive prostate cancer
- Currently the only biomarker validated for both an Active Surveillance Threshold in untreated men and Multi-Treatment Modality Threshold
- Can help identify men that that could benefit from adding hormone therapy (ADT) and those who will not (Prolaris is the only test able to do this)
Prolaris Physician Video
Learn more about the clinical utility of Prolaris in prostate cancer.
For Healthcare Providers: How to Order the Prolaris Score Test
Healthcare providers can place orders for the Prolaris Score test online at https://myriad.com/ordering-options/.
Below are additional frequently asked questions about the Prolaris test
Prolaris is a tissue-based prostate cancer marker (PCM) that helps patients and their healthcare providers understand if they may need definitive therapy or if they may be eligible for active surveillance protocol.
Testing with Prolaris is recommended before deciding on prostate cancer treatment options. Any untreated patient diagnosed with localized prostate cancer is a candidate for Prolaris testing, including those who are:
- Newly diagnosed
- Currently on active surveillance
In addition, Prolaris can help make an informed decision about whether or not adding hormone therapy (ADT) may be effective.
The Prolaris Prostate Cancer Prognostic Test analyzes positive cancer tissue from a previous prostate biopsy. The genetic test evaluates a patient’s National Comprehensive Cancer Network (NCCN) risk category as compared to the results of 46-gene expressions, including cell cycle progression genes selected based upon correlation with a patient’s prostate tumor cell proliferation. The Prolaris molecular score measures cell proliferation, not including clinical variables. The score falls between 0 and 10, with 0 being the least aggressive and 10 being the most. The Prolaris Score combined with clinical variables show the 10-year risk of prostate cancer specific mortality on active surveillance (0-100%) and 10-year metastasis risk with definitive treatment (0-100%). See a sample Prolaris test result and learn more about how to interpret these results.
Prolaris’ two clinically-validated thresholds reveal how aggressive the cancer is and what approach to treatment may be more effective (a single approach or multimodal therapy). Knowing this information gives the physician and patient confidence in determining the next steps in treatment options.
Prolaris predicts the risk of dying from prostate cancer within the next 10 years and identifies the risk of cancer spreading outside of the prostate.
Explore more information about the Prolaris Score.
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance
This study found that the clinical cell-cycle risk (CCR) score threshold is effective in segmenting patients into low- and high-risk groups for 10-year prostate cancer mortality. As a result, the research concludes that CCR (Polaris) may lead to more men being appropriately categorized into active surveillance.
Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry
This prospective study looked at the impact of the cell cycle progression (CCP) test (Prolaris) on physician recommendations and found that the test results led to meaningful changes in treatment plans.
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
This study found that the cell cycle progression (CCP) score (known as Prolaris) may aid in treating men with clinically localized prostate cancer and is the strongest independent predictor of prostate cancer mortality.